Jenkem Technology (688356) Stock Overview
Engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol (PEG), and its derivatives in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
688356 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Jenkem Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥79.27 |
| 52 Week High | CN¥118.68 |
| 52 Week Low | CN¥66.00 |
| Beta | 0.61 |
| 1 Month Change | 9.38% |
| 3 Month Change | -23.31% |
| 1 Year Change | -22.70% |
| 3 Year Change | -25.91% |
| 5 Year Change | n/a |
| Change since IPO | -78.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688356 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.9% | -4.2% | -4.7% |
| 1Y | -22.7% | -11.6% | 10.6% |
Return vs Industry: 688356 underperformed the CN Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: 688356 underperformed the CN Market which returned 10.6% over the past year.
Price Volatility
| 688356 volatility | |
|---|---|
| 688356 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 12.3% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 688356 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688356's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 304 | Xuan Zhao | www.jenkem.com |
Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol (PEG), and its derivatives in China and internationally. The company offers high molecular weight polyethylene glycol derivatives comprising branched, methoxylated, bifunctionalized, heterofunctionalized disubstituted, multi-arm, multi-arm heterofunctional disubstituted, amino-polyglycolic, N-terminated polyethylene glycol-modified, and thiol-modified polyethylene glycol PEG products; monodisperse PEG products consisting of methoxy monodisperse PEG derivatives, and monodisperse PEG derivatives with the same functional and heterofunctional groups; click chemistry; lipid nanoparticles delivery system accessories; PEG linkers, such as ADC and PROTAC linkers; PEG medical devices, which include multi-arm PEG derivatives; polyethylene glycol standards; block copolymers; PEG standards; long-acting polypeptide fatty acid side chains, including semaglutide, tirzepatide/icodec, and somapacitan intermediates; and Silkrose injectable cross-linked sodium hyaluronate gel, a passive implantable device used to correct nasolabial folds through subcutaneous injection. It also provides technical services, such as development of synthetic methods, quality research and IND application, analytical method development, and polyethylene glycolization technology services.
Jenkem Technology Co., Ltd. Fundamentals Summary
| 688356 fundamental statistics | |
|---|---|
| Market cap | CN¥4.80b |
| Earnings (TTM) | CN¥72.23m |
| Revenue (TTM) | CN¥328.26m |
Is 688356 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688356 income statement (TTM) | |
|---|---|
| Revenue | CN¥328.26m |
| Cost of Revenue | CN¥127.11m |
| Gross Profit | CN¥201.15m |
| Other Expenses | CN¥128.91m |
| Earnings | CN¥72.23m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 26, 2026
| Earnings per share (EPS) | 1.19 |
| Gross Margin | 61.28% |
| Net Profit Margin | 22.01% |
| Debt/Equity Ratio | 0% |
How did 688356 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 02:16 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jenkem Technology Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mingrui Wang | Everbright Securities Co. Ltd. |
| Chaoze Zhou | Minsheng Securities Co. |